Advertisement Covers CROI 2017


Early Reports From CROI 2017

February 12, 2017

The 24th Conference on Retroviruses and Opportunistic Infections (CROI 2017) is being held in Seattle from 13-16 February 2017.

More than 4000 researchers and health workers (and a good inclusion of community activists) meet here to work through more than 1000 studies that will be be presented at the meeting.

Luckily, the organisers support broad open access to the conference materials online, including comprehensive webcasts of all oral presentations.

Abstracts become live after the study has been presented and webcasts are usually posted the following day.

The programme for the meeting is also posted online a few days before it starts, although no details of the studies are released, other than the abstract title and authors.

Although CROI is one of the leading scientific HIV meetings, and despite the last minute reversal of the proposed U.S. travel restrictions, many delegates were suggesting even before the meeting that perhaps if similar entry restrictions are reimposed, then international medical conferences should not be held in the U.S. and that CROI could be moved to Mexico or Canada.

This detracts nothing form the excellent work from IAS-USA and U.S. scientists: it is to refuse to normalise racist policies than exclude global inclusion in medical conferences.


And the exciting news: based on the programme, 2017 is likely to have much to report, especially in the following areas:

  • New HIV treatments. Several studies present new data on new nukes (MK-8591 and GS-9131), NNRTIs (doravirine and elsulfavirine), integrase inhibitors (cabotegravir, bictegravir), and monoclonal antibodies (ibalizumab, PRO-140 and UB-421).
  • HIV and ageing. Especially the issue of neurocognitive performance.
  • Reduced drug maintenance strategies. Using two or even one drug rather than three; including studies on dolutegravir monotherapy and dual therapy with lamivudine.
  • HIV and children. Notably first results using dolutegravir in 2-6 year olds, and exposure data from crushed tablets; lopinavir super boosted with rifampicin-based TB co-treatment, and problems with starting this protease inhibitor at seven days of life. Several studies look at starting ART early in neonates.
  • Treatment access. 90:90:90 updates, including the importance on including migrants in national targets, not doing so can be a barrier to population health.
  • ART in pregnancy. Including adverse birth outcomes according to ART regimen.
  • Anal cancer. Sceening, diagnosis and treatment..
  • Coinfections -- TB and HCV. New treatments for TB and looking at TB IRIS. New hepatitis C drugs including results in people with coinfection and cirrhosis and the impact on sexual transmission in gay men.
  • Lifestyle-related changes. Smoking, diet and exercise.
  • PrEP. A major focus for prevention.
  • Advances in cure research. Including interventions in acute infection and stem sell transplantation.
  • Health literacy, demographics and viral load outcomes. Subjects close to our heart ...

Early Reports From CROI 2017

Related Stories

CROI 2017 Preview: New Research on HIV Cure and Treatment
What to Expect for CROI 2017
Don't Get Left Behind: New Scientific Findings to Be Presented at CROI 2017

This article was provided by HIV i-Base. It is a part of the publication The 24th Conference on Retroviruses and Opportunistic Infections. Visit HIV i-Base's website to find out more about their activities, publications and services.

No comments have been made.

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.


The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.